Vertex early phase 1/2 data shows promise for type 1 diabetes stem cell therapy

Vertex early phase 1/2 data shows promise for type 1 diabetes stem cell therapy

Submitted by admin on October 18, 2021 - 11:53am
Source: 
Seeking Alpha
News Tags: 
Vertex Pharmaceuticals
VX-880
type 1 diabetes
stem cells
cell therapy
clinical trials
Headline: 
Vertex early phase 1/2 data shows promise for type 1 diabetes stem cell therapy
snippet: 

Data from the first person dosed with VX-880, Vertex Pharmaceuticals' (NASDAQ:VRTX) pancreatic islet cell replacement therapy for people with type 1 diabetes, showed a 91% decrease in daily insulin requirements.

Do Not Allow Advertisers to Use My Personal information